Corvus Pharmaceuticals, Inc.: directors' dealings · United States · SEC (Form 4)

About Corvus Pharmaceuticals, Inc.

Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS) is a U.S.-based clinical-stage biopharmaceutical company headquartered in South San Francisco, California, in the San Francisco Bay Area’s core biotech cluster. The company was founded in 2014, incorporated in Delaware on January 27, 2014, and began operations in November 2014. For international investors, Corvus fits the profile of a development-stage biotech: it has no established commercial revenue base, but it may offer meaningful upside if its clinical programs continue to generate positive data and advance toward regulatory milestones. Corvus is focused on immune-mediated diseases and cancer. Its lead program is soquelitinib, an oral small-molecule candidate designed to selectively inhibit ITK, a target involved in T-cell signaling and immune-system modulation. Management positions soquelitinib as a potentially versatile asset with applications across inflammatory/autoimmune conditions and certain hematologic cancers. The company’s research narrative is built around the idea that precise immune-pathway modulation could deliver efficacy with the convenience of oral administration. While Corvus refers to a broader pipeline, recent company communications show that soquelitinib is the main value driver and the primary focus of development efforts. From a competitive standpoint, Corvus operates in a crowded field that includes large pharmaceutical companies, oncology specialists, and immunology-focused biotechs. Its differentiation lies in target selectivity, oral dosing convenience, and the possibility of a platform-like approach across multiple indications. That said, Corvus remains a clinical-stage company rather than a commercial-stage business, so its competitive position is still being validated in the clinic. Execution risk is high, and the investment case depends heavily on continued clinical success, effective capital allocation, and the ability to maintain financing flexibility. Recent company highlights have centered on data readouts for soquelitinib in atopic dermatitis and T-cell lymphoma, with multiple updates presented in 2025 and 2026 at major scientific meetings. These disclosures have helped reinforce market attention around the drug’s mechanism and potential breadth of use. Corvus also stated in its recent business updates that its cash resources were expected to fund operations into late 2026, an important consideration for shareholders given the ongoing cash burn typical of clinical-stage biotech companies. In short, Corvus Pharmaceuticals is a NASDAQ-listed U.S. biotech with a focused pipeline, a clear scientific thesis, and a high-risk/high-reward profile tied to one lead asset.